($) USD (Default)
  • ($) AUD
  • (€) EUR
  • ($) CAD
  • ($) NZD
  • (£) GBP

PT-141 Peptides

Buy PT-141 Peptides Online From Direct Sarms Norway

PT-141 research peptide, also known as Bremelanotide, is a synthetic version of the hormone alpha-MSH. PT-141 is known to activate the melanocortin receptors, which are found in the brain, to stimulate sexual arousal.

In addition to its potential as a sexual stimulant, PT-141 has also been shown to have neuroprotective properties, making it a promising area of research for the treatment of neurodegenerative diseases.

What is PT-141?

PT-141, also known as Bremelanotide, is a synthetic peptide developed for research purposes, primarily targeting sexual dysfunction and related conditions. Unlike other treatments that focus solely on blood flow, PT-141 works directly on the central nervous system, particularly the melanocortin receptors, to enhance sexual desire and arousal.

This unique action mechanism makes it a promising option for those suffering from hypoactive sexual desire disorder (HSDD) and erectile dysfunction (ED).

Given its potential, many researchers are eager to buy PT-141 to explore its efficacy in various studies. By targeting the central nervous system, PT-141 offers a promising alternative to conventional therapies, opening new avenues for understanding and treating intimate health issues more effectively.

How Does PT-141 Work?

Bremelanotide, operates through a unique mechanism that distinguishes it from other treatments targeting sexual dysfunction. Unlike conventional therapies, which primarily enhance blood flow to the genital area, PT-141 exerts its effects directly on the central nervous system. It specifically targets melanocortin receptors, which are integral to regulating sexual arousal and desire. These receptors are predominantly located in the hypothalamus, a brain region crucial for hormonal balance and motivational behaviours.

Upon administration, PT-141 binds to these melanocortin receptors, initiating a cascade of neurological events. This activation leads to an increase in dopamine levels, a neurotransmitter associated with pleasure and reward, ultimately resulting in heightened intimate desire and arousal. By influencing the brain’s pathways, bremelanotide can stimulate sexual interest and readiness without the need for physical sexual stimuli or arousal.

This central mechanism of action makes PT-141 a versatile therapy beneficial for both men and women experiencing various forms of sexual dysfunction. For individuals with hypoactive sexual desire disorder (HSDD) or erectile dysfunction (ED), bremelanotide offers a targeted, effective solution that addresses the underlying neurological aspects of these conditions, providing a comprehensive approach to improving sexual health.

PT-141 Specifications

PubChem CID: 9941379

Molecular Formula: C50H68N14O10

Molecular Weight: 1025.2 g/mol

Sequence:
Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-OH

PT-141 StructureSource: PubChem

View our PT-141 High-Performance Liquid Chromatography (HPLC) Certificate here.

What are the suggested research benefits of PT-141 Peptides?

  • Improvement in Sexual Dysfunction: PT-141’s action on the central nervous system provides a novel and promising approach to treating various forms of sexual dysfunction. This includes conditions such as hypoactive sexual desire disorder (HSDD) and erectile dysfunction (ED), which can significantly impact an individual’s quality of life. Studies indicate that by targeting the brain’s pathways involved in sexual arousal and desire, Bremelanotide offers an alternative to traditional treatments, potentially benefiting those who have not responded well to other therapies.
  • Enhanced Libido: Research shows it directly targets melanocortin receptors in the brain, potentially boosting libido in both men and women. This increased activity in the brain can lead to heightened libido, making it a promising solution for those experiencing a decrease in their libido due to various factors such as stress, age, or hormonal imbalances.
  • Adjunct for Other Therapies: This method can be used in conjunction with other treatments, such as medication, physical therapy, or alternative therapies, to enhance overall effectiveness and improve patient outcomes.
  • Neurological Mechanism: Provides insights into how brain pathways influence sexual desire, detailing the complex interactions between different brain regions and chemicals. This understanding opens new avenues for treating related conditions such as hypoactive sexual desire disorder, offering potential for more effective therapies and interventions.
  • Potential Weight Loss Aid: Early research indicates a role in weight management and overall wellness. Studies suggest that it may help in reducing body fat, improving metabolism, and supporting a healthier lifestyle when combined with a balanced diet and regular exercise.
  • Improved Vascular Health: Promotes nitric oxide production, which helps to relax and widen blood vessels. This leads to better blood vessel health, improved circulation, and numerous cardiovascular benefits, including reduced blood pressure and enhanced nutrient delivery to tissues.
  • Potential Treatment For Hemorrhage: For the treatment of acute hemorrhage, researchers are also looking into PT-141 peptide. Peptides bound to MC-1R and MC-4R alleviate ischemia and protect tissues from the onset of hemorrhagic shock induced by inadequate blood flow when PT 141 binds to these receptors.
  • Anti-Infection: Due to its potential to activate the anti-fungal and anti-inflammatory capabilities of MC-1R, PT-141 pre mixed peptide could be an alternate treatment for fungal infections.
  • Broader Therapeutic Applications: The peptide’s multifaceted mechanism not only addresses sexual dysfunction but also opens up possibilities for studying and treating a variety of other health issues. This could include conditions such as cardiovascular diseases, metabolic disorders, and even certain neurological conditions, making it a versatile candidate in the realm of medical research.
  • Versatile Administration: This compound is available in various forms, including nasal sprays and injections, making it highly adaptable for different research protocols. Its flexibility in administration allows researchers to tailor the delivery method to specific study requirements, ensuring optimal results and greater accuracy in experimental outcomes.
  • Enhanced Understanding of Dopamine: Offers a deeper understanding of dopamine’s role in pleasure and reward systems, valuable for various psychological and physiological studies.
  • Potential Minimal Side Effects: Compared to traditional therapies, bremelanotide may present with fewer adverse reactions, such as nausea, headache, or dizziness. This reduction in side effects can significantly improve patient compliance and overall satisfaction, making it a more attractive option for long-term treatment plans.
  • Clinical Trials and Efficacy: Ongoing clinical trials are exploring the efficacy of PT-141 in enhancing sexual satisfaction and reducing symptoms of sexual dysfunction. Preliminary data indicates promising interactions with the central nervous system, leading to improved desire and arousal, thus making it a valuable candidate for future therapeutic applications.

What PT-141 products are available?

PT-141 Nasal Spray

PT-141 Nasal Spray 15ml

Buy PT-141 nasal spray (Bremelanotide) from Norway Direct Sarms, available in size 15ml and 30ml bottles for research studies.

PT-141 Peptide Vial

pt-141-peptide-vial-10mg

Buy PT-141 Peptide 10mg Vial for research from Direct Sarms Norway. Also available as a kit, which includes bacteriostatic water and syringes. This offers convenience to researchers by simplifying the process of reconstituting the peptide.

Frequently Asked Questions (FAQ’s) about PT-141 Peptides

PT-141 FAQ

What is the legal status of PT-141?

While the U.S. Food and Drug Administration (FDA) has approved PT-141, branded as Vyleesi, for treating hypoactive sexual desire disorder (HSDD) in premenopausal women, its approval is currently restricted to this specific use. Its regulatory status differs across various regions and therefore researchers need to know the laws in their own region.

In the United Kingdom, PT-141 has not yet received approval from the Medicines and Healthcare products Regulatory Agency (MHRA). Consequently, its usage remains limited to clinical trials and off-label prescriptions. Healthcare professionals and researchers continue to monitor ongoing studies and regulatory developments to determine its future availability in the UK market.

Similarly, in Australia, PT-141 has not been approved by the Therapeutic Goods Administration (TGA). The absence of regulatory approval signifies that bremelanotide is not yet commercially available for the treatment of HSDD. However, like in the UK, ongoing research and clinical trials are closely scrutinised, and future approval may depend on further evidence of efficacy and safety.

Both the UK and Australia are expected to follow the global scientific community’s evaluations of bremelanotide’s therapeutic potential, which may eventually influence regulatory decisions.

What are the side effects of PT-141?

Like many research peptides, bremelanotide comes with potential side effects, including redness, nausea, headaches, and occasional discomfort at the injection site. It’s crucial for researchers to monitor participants closely and instruct them to report any adverse effects immediately.

Prompt reporting allows for swift medical attention and necessary adjustments to patient care strategies, ensuring the safety and well-being of all participants.

Can PT-141 help with weight loss?

Preliminary research suggests that PT-141 may aid in weight management by reducing body fat and improving metabolism, although more studies are needed to confirm these findings.

How should bremelanotide be stored?

Bremelanotide should be stored according to the supplier’s guidelines, usually in a cool, dry place away from direct sunlight, to maintain its stability and efficacy.

Further Reading

For more information, explore our latest blog posts dedicated to PT-141 peptides.

Buy PT-141 Peptides Today!

Researchers looking to buy PT-141 for their studies can find it available in various forms such as nasal sprays and subcutaneous injections (e.g., the peptide vial and the PT-141 Pre-mixed Pen 10mg). When considering to Buy PT-141, it is essential to source from reputable suppliers, such as Norway Direct Sarms, to ensure the quality and integrity of the peptide, which is fundamental for achieving reliable and consistent research outcomes.


Scientific References

[1] J.G.Pfaus, A.Shadiack, T.Van.Soest, et al (2004) Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist – Proceedings of the National Academy of Sciences USA, 2004 Jul 6;101(27):10201-4.

[2] A.H.Clayton, S.E.Althof, S.Kingsberg, et al (2016) Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial – Sage Journals, Womens Health (Lond), 2016 Jun;12(3):325-37.

[3] R.E.Nappi, K.Wawra, and S.Schmitt (2006) Hypoactive sexual desire disorder in postmenopausal women – Gynecological Endocrinology, 2006 Jun;22(6):318-23.

[4] M.K.Miller, J.R.Smith, J.J.Norman, et al (2018) Expert opinion on existing and developing drugs to treat female sexual dysfunction – Expert Opinion Emerging Drugs, 2018 Sep;23(3):223-230.

[5] J.A.Simon, S.A.Kingsberg, D.Portman, et al (2019) Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder – Obstetrics and Gynecology, 2019 Nov; 134(5): 909–917.

[6] A.N.Edinoff, N.M.Sanders, K.B.Lewis, et al (2022) Bremelanotide for Treatment of Female Hypoactive Sexual Desire – Neurology International, 2022 Mar; 14(1): 75–88.

[7] C.Spana, R.Jordan, S.Fischkoff (2022) Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials – Diabetes Obesity and Metabolism, 2022 Jun;24(6):1084-1093.

[8] Hai-xia Ji ,Yu-lian Zou ,Jing-jing Duan, et al (2013) The Synthetic Melanocortin (CKPV)2 Exerts Anti-Fungal and Anti-Inflammatory Effects against Candida albicans Vaginitis via Inducing Macrophage M2 Polarization – PLOS One Journal, Published: February 14, 2013.

 


ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Norway Direct Sarms website is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.